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Abstract
Background: The clinical course of tick-borne encephalitis (TBE), a disease caused by TBE virus, ranges from
asymptomatic or mild influenza-like infection to severe debilitating encephalitis or encephalomyelitis. Despite the
medical importance of this disease, some crucial steps in the development of encephalitis remain poorly
understood. In particular, the basis of the disease severity is largely unknown.
Methods: TBE virus growth, neutralizing antibody response, key cytokine and chemokine mRNA production and
changes in mRNA levels of cell surface markers of immunocompetent cells in brain were measured in mice with
different susceptibilities to TBE virus infection.
Results: An animal model of TBE based on BALB/c-c-STS/A (CcS/Dem) recombinant congenic mouse strains
showing different severities of the infection in relation to the host genetic background was developed. After
subcutaneous inoculation of TBE virus, BALB/c mice showed medium susceptibility to the infection, STS mice were
resistant, and CcS-11 mice were highly susceptible. The resistant STS mice showed lower and delayed viremia,
lower virus production in the brain and low cytokine/chemokine mRNA production, but had a strong neutralizing
antibody response. The most sensitive strain (CcS-11) failed in production of neutralizing antibodies, but exhibited
strong cytokine/chemokine mRNA production in the brain. After intracerebral inoculation, all mouse strains were
sensitive to the infection and had similar virus production in the brain, but STS mice survived significantly longer
than CcS-11 mice. These two strains also differed in the expression of key cytokines/chemokines, particularly
interferon gamma-induced protein 10 (IP-10/CXCL10) and monocyte chemotactic protein-1 (MCP-1/CCL2) in the
brain.
Conclusions: Our data indicate that the genetic control is an important factor influencing the clinical course of TBE.
High neutralizing antibody response might be crucial for preventing host fatality, but high expression of various
cytokines/chemokines during TBE can mediate immunopathology and be associated with more severe course of
the infection and increased fatality.
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Background
Flaviviruses, a group of small, enveloped, positive-sense,
single-stranded RNA viruses, include several medically
very important pathogens. Especially Japanese encephal-
itis virus, yellow fever virus, West Nile virus, dengue
virus, Murray Valley encephalitis virus and tick-borne
encephalitis virus (TBEV) are responsible for large out-
breaks of fatal encephalitis or hemorrhagic fevers at di-
verse geographical regions around the world. Tick-borne
encephalitis (TBE), a disease caused by TBEV, represents
one of the most important and serious neuroinfections
in Europe and northeastern Asia. More than 13,000 clin-
ical cases of TBE, including numerous deaths, are
reported annually. Despite the medical importance of
this disease, some crucial steps in the development of
encephalitis remain poorly understood. In humans,
TBEV may produce a variety of clinical symptoms, from
an asymptomatic disease (70-90% of cases) to a fever
and acute or chronic progressive encephalitis. This is
influenced by a variety of factors, e.g., the inoculation
dose and virulence of the virus [1], the age, sex and im-
mune status of the host [2], and also susceptibility based
on the host’s genetic background. Studies of animal
models and epidemiological studies in humans have
shown that many apparently non-hereditary diseases, in-
cluding infectious diseases, develop predominantly in
genetically predisposed individuals and that this predis-
position is caused by multiple genes [3]. In humans, a
functional Toll-like receptor 3 gene may be a risk factor
for TBEV infection [4]. A deletion within the chemokine
receptor CCR5 (CCR5Δ32), which plays an important
role in leukocyte transmigration across the blood–brain
barrier, is significantly more frequent in patients with
TBE than in TBE-naïve patients with aseptic meningitis
[5]. Moreover, the severity and outcome of TBE is asso-
ciated with variability in the 2'-5'-oligoadenylate synthe-
tase gene cluster (family members are interferon-
induced antiviral proteins that play an important role in
the endogenous antiviral pathway) [6] and with the
rs2287886 single nucleotide polymorphism located in
the promoter region of the human CD209 gene [7]. This
gene encodes dendritic cell-specific ICAM3-grabbing
nonintegrin (DC-SIGN), a C-type lectin pathogen-
recognition receptor expressed on the surface of den-
dritic cells and some types of macrophages [7]. Taken
together, polymorphism in various genes may largely in-
fluence the sensitivity of the host to the infection and
determine the severity of this disease.
While in humans involvement of genetic factors in the
control of the susceptibility to TBEV infection is quite
difficult to investigate, mice provide a useful small ani-
mal model for such a kind of study [8]. Mice are suitable
animal models of infection with TBEV because they can
reproduce symptoms and physiopathological markers as
observed in severe cases in humans. A high susceptibility
of most laboratory mouse strains to flavivirus infection
has been genetically mapped to a stop codon mutation
in the coding region of the 2´-5´-oligoadenylate synthe-
tase gene Oas 1b [9].
In our study, we developed an animal model of TBE
showing several manifestations of the disease in relation
to the genetic background, which is not based on the
previously published mutation in the Oas 1b gene. We
analyzed the sensitivity to TBEV in CcS/Dem (CcS) re-
combinant congenic (RC) strains of mice [10] derived
from the background strain BALB/cHeA (BALB/c) and
the donor strain STS. Each CcS strain contains a unique
random set of about 12.5% genes from the donor strain
STS and 87.5% genes from the background strain
BALB/c [10]. This system has been very useful in re-
search of bacterial [11] and parasitic [12-18] diseases,
as well as in cancer [19-23].
In this study, we identified mouse strains that exhibit
high, intermediate and low sensitivity to TBEV infection.
Virus growth, key cytokine and chemokine mRNA pro-
duction in the brain and neutralizing antibody response
were measured. Our data suggest that the genetic con-
trol represents one of the important factors that influ-
ence the clinical course of TBE and that also other genes
than the previously described Oas 1b are involved in the
determination of host susceptibility to the infection. While
high neutralizing antibody response might be crucial for
preventing host fatality, high local expression of various
proinflammatory cytokines/chemokines in the brain dur-
ing TBE can be associated with a more severe course of
the infection and higher fatality. Our data may be instru-
mental in the development of future therapeutic strategies
aimed at treating or preventing TBE neuropathogenesis.
Material and methods
Mice
Specific pathogen-free mice of parental strains BALB/c,
STS and ten randomly selected RC strains (see below)
were used in the experiments. RC strains were in more
than 90 generation of inbreeding and therefore highly
homozygous. Genetic composition of the strain CcS-11
is schematically shown in Figure 1A. Sterilized pellet diet
and water were supplied ad libitum. In all experiments,
female mice aged 12–15 weeks at the time of infection
were used. The mice were housed in plastic cages with
wood-chip bedding, situated in a specific pathogen-free
room with a constant temperature of 22°C and a relative
humidity of 65%. The research complied with all rele-
vant European Union guidelines for work with animals
and was in accordance with the Czech national law and
guidelines on the use of experimental animals and pro-
tection of animals against cruelty (Animal Welfare Act
no. 246/1992 Coll.). The protocol was approved by the
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Committee on the Ethics of Animal Experiments of the
Institute of Parasitology and of the Departmental Expert
Committee for the Approval of Projects of Experiments
on Animals of the Academy of Sciences of the Czech
Republic (permit no. 165/2010).
Virus infection
All experiments were performed with European proto-
typic TBEV strain Neudoerfl (a generous gift from Prof.
F.X. Heinz, Medical University of Vienna). The virus
was originally isolated from the tick Ixodes ricinus in
Austria in 1971 and has been extensively characterized
including its complete genome sequence and the deter-
mination of the three-dimensional structure of its enve-
lope protein [24]. This strain was passaged four times in
brains of suckling mice.
Mice were infected either subcutaneously (s.c.) into
the scruff of the neck with 103 pfu or intracerebrally (i.c.)
with 10 pfu of the virus. Mice were scored for mortality
for a period of 28 days post-infection (p.i.), and survival
curves were established.
Plaque assay
The virus titers were determined by plaque assay on por-
cine kidney stable cell (PS) monolayers under a
carboxymethyl-cellulose overlay, as described previously
[25]. Infectivity was expressed as plaque-forming units
(pfu) per ml (or g of brain tissue).
Virus growth in mice
At the given time point p.i., three mice of each group
were anesthetized and killed by cervical dislocation.
Specimens of blood serum and brains were collected.
Brains were individually weighed and prepared as 20%
suspensions in phosphate-buffered saline (PBS) using
TissueLyser II (Qiagen). The homogenate was clarified
by centrifugation at 14,000× g for 10 min at 4°C, and
supernatant fluids were titrated by plaque assay on PS
cells. The detection thresholds were 1.4 log10 pfu/ml for
serum and 2.1 log10 pfu/g for brain suspensions.
Real-time quantitative RT-PCR
Real-time quantitative PCR was performed by the
TaqMan Gene Expression Assays (Applied Biosystems)
as previously described [26]. RNA was isolated from the
brain tissue pellets using RNeasy Mini Kit (Qiagen),
according to the recommendations of the manufacturer.
cDNA was synthesized using a High Capacity RNA-to-
cDNA Kit (Applied Biosystems), according to the
manufacturer's protocol. The synthesized cDNAs were
used as templates for real-time PCR. In quantitative RT-
PCR the following primer probe sets from Applied
Biosystems were used: TNFα (Mm00443258_m1), IFNγ
(Mm 01168134_m1), CCL2/MCP1 (Mm 00441242_m1),
CCL3/MIP1α (Mm00441258_m1), CCL4/MIP1β (Mm00-
443111_m1), CCL5/RANTES (Mm01302428_m1), CD4
(Mm00442754_m1), CD8b1 (Mm00438116_m1), CD11β
Figure 1 Chromosomal composition of the mouse strains used in this study based on precise chromosomal mapping. The RC strain
CcS-11 contains a random set of ~12.5% genes from strain STS donor strain and 87.5% genes from strain BALB/c (background strain). Sex
chromosomes are not shown in this figure (A). Survival of mice after s.c. inoculation of TBEV. Mice (n = 10 per group) were inoculated with 103
pfu of TBEV and observed for lethality (B). Survival of mice (BALB/c, n = 8; CcS-11, n = 9; STS, n = 7) after i.c. inoculation of 10 pfu of TBEV (C).
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(Mm00434455_m1), CD19 (Mm00515420_m1), IL1a
(Mm00439620_m1), IL1β (Mm01336189_m1), IL6
(Mm00446190_m1), IL2 (Mm00434256_m1), IL4 (Mm00-
445259_m1), IL5 (Mm00439646_m1), IL10 (Mm00439-
614_m1) and IP10/CXCL10 (Mm00445235_m1). Mouse
beta actin was used as a housekeeping gene. Amplification
conditions were: 2 min at 50°C; 10 min at 95°C; 40 cycles
of denaturation at 95°C for 15 s and annealing/extension
at 60°C for 1 min.
Quantification of gene expression was performed using
the comparative CT method and reported as the fold
difference relative to the housekeeping gene. To calcu-
late the fold change, the CT of the housekeeping gene
was subtracted from the CT of the target gene to yield
the ΔCT. Change in expression of the normalized target
gene was expressed as 2-ΔΔCT where ΔΔCT = ΔCT sam-
ples - ΔCT controls as previously described [27].
Plaque reduction neutralization test
The titers of neutralizing antibodies against TBEV in
mouse sera were determined by the plaque reduction
neutralization test (PRNT) as described by Bárdoš [28]
with slight modifications. Sera (including positive and
negative controls) were diluted 1:4 in L-15 medium
(Leibowitz; Sigma) supplemented with 1% antibiotics
(penicillin, streptomycin, amphotericin B; Sigma) and 3%
inactivated newborn calf serum. After inactivation of the
virus and complement in the sera by heating at 56°C for
30 min, two-fold serial dilutions of the samples in L-15
medium were incubated with 103 pfu of TBEV (the virus
test dose was adjusted so that it caused almost confluent
plaques, 90-95% cytolysis) for 90 min at 37°C; 5 × 104
PS cells were added to each well. After 6 days of incuba-
tion, the cell supernatant was removed and cells were fixed
and stained as described previously [25]. The last dilution
of serum that caused an 80-100% reduction in cytolysis of
the virus test dose was regarded as the serum titer.
Statistical analysis
The differences in survival time of infected mice were ana-
lyzed by survival analysis (log-rank Mantel-Cox test). All
other data were analyzed by one-way ANOVA (Newman-
Keuls multiple comparison test). Data without normal dis-
tribution were transformed by use of the X’ = ln(X) for-
mula. All analyses were performed using GraphPad Prism
5.00 (GraphPad Software, Inc., USA); p-values < 0.05 were
considered significant.
Results
CcS/Dem RC mouse strains show diverse susceptibilities
to infection with TBEV
To study the susceptibility of mice to TBEV, we infected
females of the strains BALB/c, STS and RC strains CcS-
3, CcS-7, CcS-9, CcS-11, CcS-15 and CcS-16 s.c. with
104 pfu of TBEV, and survival was recorded. Mice with
different genotypes exhibited different susceptibilities to
TBEV (Additional file 1: Figure S1). The most striking dif-
ferences in survival rates and mean survival times were
seen in parental strains BALB/c and STS, and RC strain
CcS-11 (Figure 1B). CcS-11 mice were shown to be most
susceptible, while STS mice are the least susceptible.
BALB/c mice exhibited intermediate susceptibility. Mean
survival time (MST) of the CcS-11 mice was 13.1 ± 3 days,
BALB/c 22.8 ± 7.5 days and STS 29.7 ± 4.1 days (p < 0.05).
Differences were also found in case of survival rates.
While all CcS-11 mice died following the infection, 40% of
infected BALB/c and 90% of STS mice survived until the
end of the experiment (Figure 1B). STS mice remained
free of any clinical signs of the disease during the whole
experiment (including that one mice that died); BALB/c
mice exhibited signs of rough fur, hunching or back limb
paralysis. Some CcS-11 mice had similar signs as BALB/c
mice, but some died without previous appearance of any
kind of signs.
In order to test the susceptibility to the TBEV infec-
tion if host factors before viral entry of the CNS are
avoided, we infected females of the strains BALB/c, STS
and RC strains CcS-3, CcS-4, CcS-5, CcS-7, CcS-9, CcS-
11, CcS-12, CcS-15, CcS-18 and CcS-20 i.c. with 10 pfu
of TBEV. In this case, all mouse strains were susceptible
to the infection. Most strains died almost at the same
time p.i., i.e., between days 10 and 11 p.i. (Additional file 1:
Figure S2). However, differences were seen in the MST
in case of CcS-11 (MST of 8.0 ± 0.7 days), BALB/c
(MST of 9.5 ± 0.5 days) and STS strains (MST of 12.4 ±
2.7 days) (p < 0.05; Figure 1C). Therefore, also factors
acting directly in the CNS of the infected mice may
influence the survival time. For all subsequent experi-
ments, mice of strains CcS-11, BALB/c and STS were
selected as representatives of high-, medium- and low-
susceptible hosts.
Virus load in serum and brain of TBEV-infected mice
Serum samples of BALB/c, CcS-11 and STS mice were
harvested for titration at various time points after s.c. in-
oculation of TBEV. The virus titers in individual samples
were determined by plaque assay on PS cells. While the
peak of viremia was observed in BALB/c and CcS-11
mice reaching 2–2.5 log10 pfu/ml at days 3 and 4 p.i., no
virus was detected at the same time points in STS mice
(p < 0.05). STS mice had only traces of the virus in
serum (<2 log10 pfu/ml) at later time intervals, i.e. at day
5, 6 and 8 p.i. (Figure 2A).
Virus load in the brain after s.c. inoculation was
assayed at day 13 p.i., i.e. at the time point when most of
the CcS-11 and BALB/c mice exhibited neurological
signs of the infection (Figure 2B). No difference was
found in the virus titer in brain of the infected BALB/c
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and CcS-11 mice (titer reaching 6–7 log10 pfu/g), but a
much lower titer was observed in brains of infected STS
mice (approximately 3 log10 pfu/g; p < 0.005).
After i.c. inoculation, a dynamics of virus growth in
the brain was investigated. Increasing virus titers were
seen before mice showed signs of the infection. The
virus growth was almost identical in all three mouse
strains, reaching its maximum at day 7 (8 log10 pfu/g)
(Figure 2C). The only difference was observed at day 2,
when BALB/c mice had slightly higher virus titers in the
brain than CcS-11 mice (p < 0.05).
Immune cell accumulation in the CNS of TBEV infected
mice
Accumulation of immunocompetent cells in the brain of
the infected BALB/c, STS and BALB/c mice was quanti-
fied as the changes in mRNA levels of cell surface
markers of B-cells (CD19), T-helper cells (CD4), cyto-
toxic T-cells (CD8β) and macrophage/monocyte/gran-
ulocyte/NK cells (CD11b).
In case of s.c. inoculation of TBEV (Figure 3A), the
immune cell antigen mRNA accumulation was assayed
at day 13 p.i. During our preliminary experiments, mice
were also sampled and assayed at days 8 and 10 p.i. (data
not shown). However, at these time points only some
mice had virus in their CNS, making the results too vari-
able. The day 13 p.i. was the first interval when all mice
had virus in their brains. CD4, CD8β and CD11b mRNA
levels in the brains of infected mice at day 13 p.i. became
significantly higher than those of normal uninfected
mice at day 13. p.i. However, CD19 mRNA levels did not
significantly increase in BALB/c and CcS-11 mice, but
became elevated in STS mice (p < 0.05).
After i.c. inoculation of TBEV (Figure 3B), the dynam-
ics of immune cell accumulation in the CNS was investi-
gated at days 2, 4, 6 and 7 p.i. No significant increase in
the CD19 mRNA levels was seen in any of the investi-
gated mouse strain at 4, 6 and 7 days p.i. Levels of
CD11b mRNA increased in brains of STS mice as early
as at day 2 and 4 p.i., whereas no increase was observed
in BALB/c and CcS-11 mice until day 4 p.i. From day 6,
a slight but significant increase of CD11b levels was ob-
served in all mice tested; however, there was no differ-
ence between the individual mouse strains. CD4 and
CD8β mRNA levels increased remarkably (10-20-fold in-
crease of CD4 mRNA and 100-200-fold increase of CD8β
mRNA compared to negative controls) in all investigated
mouse strains from day 6 p.i. Higher levels of CD4 as well
as CD8β mRNA levels were detected in brains of infected
STS than BALB/c mice at day 6 p.i. (p < 0.05).
Expression of key inflammatory cytokines/chemokines in
brains of TBEV infected mice
The levels of mRNA specific for a broad range of cyto-
kines (TNF-α, IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6
and IL-10) and chemokines (CCL2 (chemokine ligand 2)/
MCP-1 (monocyte chemotactic protein-1), CCL3/MIP-1α
(macrophage inflammatory protein-1α), CCL4/MIP-1β
(macrophage inflammatory protein-1β), CCL5/RANTES
(regulated upon activation, normal T-cell expressed and
secreted) and interferon-γ-inducible protein-10 (IP-10)/
CXCL/10) were quantified in brains of TBEV infected
BALB/c, CcS-11 and STS mice by real-time RT-PCR, and
Figure 2 Viral loads in sera of BALB/c, CcS-11 and STS mice
after s.c. inoculation of 103 pfu of TBEV. Virus titer was
determined by plaque assay on PS cells (A). Virus titer in brains of
BALB/c, CcS-11 and STS mice after s.c. inoculation was assayed on
day 13, i.e., at the time of clinically manifest neuroinfection (B). Virus
titer in brains of BALB/c, CcS-11 and STS mice after i.c. inoculation of
10 pfu of TBEV (C). The detection thresholds were 1.4 log10 pfu/ml
for serum and 2.1 log10 pfu/g for brain suspensions.
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Figure 3 Immune/inflammatory cell accumulation in brains of BALB/c, CcS-11 and STS mice after s.c. (13 day p.i.) (A) or i.c. (B)
inoculation of TBEV. Immune cell accumulation in the CNS was quantified as the changes in mRNA levels of cell surface markers of B-cells
(CD19), T-helper cells (CD4), cytotoxic T-cells (CD8β) and macrophage/monocyte/granulocyte/NK cells (CD11b), and normalized to expression of
housekeeping gene, mouse beta actin. Data are expressed as the mean + standard deviation of the fold increase in the level of the mRNA in
comparison to uninfected control mice. *p < 0.05; **p < 0.005 (n = 3 mice per group and experiment).
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standardized to the levels of the housekeeping gene, beta
actin, mRNA (Figures 4 and 5).
After the s.c. inoculation of TBEV (Figure 4), the levels
of cytokine/chemokine mRNA were measured on day 13
p.i. During our preliminary experiments, mice were also
sampled and assayed at days 8 and 10 p.i. (data not
shown). However, at these time points only some mice
had virus in their CNS, making the results too variable.
The day 13 p.i. was the first interval when all mice had
virus in their brains. Significantly increased mRNA levels
of TNF-α, IFNγ, IL-1α, IL-1β, IL-2, IL-6, IL-10, MCP-1,
RANTES and IP-10 were seen in the TBEV-infected mice
of all strains when compared to negative uninfected con-
trols at day 13 p.i. In case of CCL3/MIP-1α (Figure 4D)
and CCL4/MIP-1β (Figure 4E) mRNA, only sensitive
strains BALB/c and CcS-11 exhibited upregulated expres-
sion after the TBEV infection, whilst the expression in
infected STS mice was not changed. The levels of IL-5
mRNA were increased only in brains of infected CcS-11
mice (Figure 4J), but the infection did not affect the ex-
pression of this cytokine in brains of BALB/c and STS
mice. The levels of IFN-γ were the highest in brains of
infected CcS-11 mice; BALB/c mice exhibited higher
levels than STS (p < 0.0005; Figure 4A). The levels of
upregulation of IL-6 mRNA expression were similar in
BALB/c and CcS-11 mice, but both these strains exhibited
significantly enhanced expression in comparison to STS
mice (p < 0.005; Figure 4K).
Major differences in the cytokine mRNA expression
among the infected BALB/c, CcS-11 and STS mice were
Figure 4 Cytokines and chemokines produced in brains of BALB/c, CcS-11 and STS mice inoculated s.c. with 103 pfu of TBEV. The brains
were collected and cytokine production assayed on day 13 p.i. The levels of cytokine/chemokine mRNA [IFNγ (A); TNFα (B); MCP-1 (C); MIP-1α (D);
MIP-1β (E); RANTES (F); IL-1α (G); IL-1β (H); IL-2 (I); IL-5 (J); IL-6 (K); IL-10 (L) and IP-10 (M)] were quantified by real-time RT-PCR and standardized
to the mRNA levels of the housekeeping gene, beta actin. Data are expressed as the mean + standard deviation of the fold increase in the level
of the mRNA in comparison to uninfected control mice. *p < 0.05; **p < 0.005, ***p < 0.0005. (n = 3 mice per group and experiment).
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Figure 5 (See legend on next page.)
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seen in case of MCP-1 (Figure 4C) and IP-10 (Figure 4M)
mRNA. CcS-11 mice had the highest levels of MCP-1
and IP-10 mRNA in brains, while BALB/c had lower
levels of MCP-1 and IP-10 mRNA when compared to
CcS-11 mice, but higher when compared to STS mice
(Figure 4C, M).
The dynamics of the changes in cytokine/chemokine
mRNA expression was investigated at days 2, 4, 6 and 7
after i.c. inoculation of TBEV (Figure 5). No changes in
the levels of IL-5 mRNA (Figure 5I) were observed in
any of the studied mouse strains at any time point.
TNF-α (Figure 5B), CCL2/MCP-1 (Figure 5C) and
CCL4/MIP-1β (Figure 5D) mRNA levels increased sig-
nificantly from day 2 p.i. A significant increase in the
level of mRNA for IFN-γ, IL-1β, IL-2, IL-6 and CCL5/
RANTES (Figure 5 A, G, H, J, E) was seen from day 4 p.
i. Expression of IL-1α mRNA was enhanced from the
day 6 p.i. (Figure 5F). A large variation in the values of
MIP-1α, IL-10 (data not shown) and IL-2 (Figure 5H)
mRNA was observed between the individual mice within
the strain each day after the i.c. inoculation of TBEV.
IFN-γ mRNA levels were much higher in CcS-11 mice
at day 7 p.i. when compared to STS mice (p < 0.05).
Similarly, the lowest levels of IL-6 (p < 0.0005) and
CCL5/RANTES (BALB/c vs. STS, p < 0.05; CcS-11 vs.
STS, p < 0.005) mRNA were detected in STS mice ver-
sus BALB/c and CcS-11 mice at day 7 p.i. In contrast,
STS mice had very enhanced levels of IL-1β mRNA at
day 7 p.i. in comparison to BALB/c and CcS-11 mice
(p < 0.05). The greatest differences among the infected
BALB/c, CcS-11 and STS mice were seen in case of
MCP-1 and IP-10 mRNA. CcS-11 mice had the highest
levels of MCP-1 mRNA in brains at days 4, 6 (p < 0.05)
and 7 p.i. (BALB/c vs. STS, p < 0.005; CcS-11 vs. BALB/c,
p < 0.05; CcS-11 vs. STS, p < 0.0005). The levels of
IP-10 mRNA were the highest in CcS-11 mice at all in-
vestigated time points p.i., the highest differences being
observed at day 6 p.i. (BALB/c vs. CcS-11 and STS vs.
CcS-11, p < 0.005) and at day 7 p.i. (BALB/c vs. CcS-11,
p < 0.005, and STS vs. CcS-11, p < 0.0005). BALB/c had
lower levels of IP-10 mRNA than CcS-11 mice (p < 0.05),
but higher than STS mice (p < 0.05). A correlation
between the IP-10 mRNA levels with the sensitivity of
mice to the TBEV infection was observed (Figures 1C,
5K). No changes in the expression of IL-4 mRNA were
seen in any mouse strain after either s.c. or i.c. TBEV
inoculation (data not shown).
TBEV-specific antibodies elicited in infected mice
In order to compare the host’s humoral immune re-
sponse in the infected BALB/c, CcS-11 and STS mice
after s.c. inoculation of TBEV, TBEV-specific antibodies
were tested at days 5, 8, 10 and 13 p.i.. The titer of neu-
tralizing antibodies was determined by PRNT (plaque
reduction neutralization test) assay. Before day 10, a very
low titer of neutralizing antibodies and no difference be-
tween the strains were observed (data not shown). At
day 10 p.i., very low titers of neutralizing antibodies were
found in serum of BALB/c and CcS-11 mice (less than
1:20), but STS mice exhibited neutralizing titers of 1:100
(p < 0.005). At day 13 p.i., no increase in the titer of neu-
tralizing antibodies was seen in CcS-11 mice. BALB/c
mice exhibited neutralizing titers of 1:100, but STS mice
had titers reaching 1:640 (p < 0.0005) (Figure 6). No neu-
tralizing activity was detected in sera from control unin-
fected mice.
Discussion
Host genotype as an important determinant of
susceptibility to TBEV infection
Mice provide a useful tool for study of human TBE,
since they recapitulate the pathological and pathophysio-
logical processes seen in severe human TBE cases. How-
ever, biological and virological markers indicating the
severity of TBE in mice as well as in humans remain
Figure 6 TBEV-specific antibody responses in BALB/c, CcS-11
and STS mouse sera (n = 3 mice per group) after s.c.
inoculation of TBEV. The plaque reduction neutralization test in PS
cells was used to quantitate anti-TBEV neutralizing antibodies. Data
are expressed as the geometric mean titer (GMT) + standard
deviation. *p < 0.05; **p < 0.005, ***p < 0.0005.
(See figure on previous page.)
Figure 5 Cytokines and chemokines produced in brains of BALB/c, CcS-11 and STS mice inoculated i.c. with 10 pfu of TBEV. The levels
of cytokine/chemokine mRNA [IFNγ (A); TNFα (B); MCP-1 (C); MIP-1β (D); RANTES (E); IL-1α (F); IL-1β (G); IL-2 (H); IL-5 (I); IL-6 (J); and IP-10 (K)]
were quantified by real-time RT-PCR and standardized to the mRNA levels of the housekeeping gene, beta actin. Data are expressed as the
mean + standard deviation of the fold increase in the level of the mRNA in comparison to uninfected control mice. *p < 0.05; **p < 0.005,
***p < 0.0005 (n = 3 mice per group and experiment).
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unclear. The severity of TBE can be influenced by a var-
iety of factors, e.g., the inoculation dose and virulence of
the virus [1], the age, sex and immune status of the host
[2], and susceptibility based on the host’s genetic back-
ground. Generally, age of the host is the most common
host risk factor identified for severe forms of flavivirus
encephalitis [29]. However, genetic host risk factors play
an important role in the development of severe flaviviral
neurological diseases as well. Several genetic host factors
associated with the severe forms of flavivirus encephalitis
have been identified. These include polymorphisms in
HLA-A and HLA-B, polymorphism located in the pro-
moter region of the human CD209 gene [7] and func-
tional Toll-like receptor 3 gene [4], deletion in CCR5 [5]
and variability in 2´-5´-oligoadenylate synthetase gene
cluster [6]. In our study, we developed a new mouse
model of hosts differing in the susceptibility to TBEV in-
fection based on CcS/Dem RC mouse strains. We ob-
served clearly different patterns in the susceptibility of the
CcS/Dem RC strains to s.c. infection with TBEV. Out of
the eight strains tested, one (STS) exhibited low suscepti-
bility, five intermediate susceptibility (CcS-3, CcS-7, CcS-9,
CcS-16 and BALB/c) and two strains (CcS-11 and CcS-
15) high susceptibility (Additional file 1: Figure S1). Dif-
ferences in MST between the strains CcS-11, BALB/c and
STS were also observed after i.c. inoculation of TBEV, i.e.,
CcS-11 mice had the shortest MST, BALB/c medium
MST and STS the longest MST and higher survival
(Figure 1C). These differences indicate the presence of
TBEV susceptibility genes. Different susceptibility to virus
infection in recombinant inbred strains between BALB/c
and STS mice was also observed in case of infection with
murine coronavirus [30]. After i.c. inoculation of 100 pfu
of murine coronavirus, all BALB/c mice were highly sus-
ceptible and died; in contrast, STS mice were shown to be
partially resistant, with a mortality rate of 30%, longer sur-
vival times and lower rates of virus production [30]. In our
study, RC strain CcS-11, which contains approximately
12.5% genes of the donor strain STS and 87.5% genes of
the background strain BALB/c, was more sensitive to
TBEV infection than both parental strains BALB/c and
STS. The observations of progeny having a phenotype be-
yond the range of the phenotype of its parents are not rare
in traits controlled by multiple genes [18]. Such an obser-
vation may be due to multiple gene-gene interactions of
quantitative trait loci, which in new combinations of these
genes in RC or chromosomal substitution can lead to the
appearance of new phenotypes that exceed their range in
parental strains [18]. Another possibility is when some
progeny receives predominantly susceptible alleles from
both parents. These susceptible alleles are distinct from
genes H2, Cd209, Tlr3, Ccr5 and Oas1b, which are in-
volved in genetic control of susceptibility to flavivirus en-
cephalitis (see above), because these genes are in CcS-11
localized on segments derived from the background
BALB/c strain [Figure 1A and Mouse Genome Informatics
(http://www.informatics.jax.org/)]. We also cannot exclude
the possibility of a spontaneous mutation appearing dur-
ing inbreeding and causing the unique phenotype [18].
Similarly to our study, CcS-11 mice were more susceptible
to infection with Leishmania tropica [18] and to
Trypanosoma brucei brucei [31] than both parental mouse
strains. However, CcS-11 is more resistant to L. major
than BALB/c [32].
TBEV replication rate in infected mice is not the main
factor influencing survival
We attempted to identify biological markers that could
be related to differences in survival rates of the highly
susceptible (CcS-11), medium susceptible (BALB/c) and
lowly susceptible (STS) mice infected with TBEV. STS
mice had very low and delayed viremia when compared
with BALB/c and CcS-11 mice after s.c. inoculation. All
mice showed brain infection, but lower titers were
detected in brains of STS mice, while BALB/c and CcS-
11 mice showed higher titers for 3–4 log10 pfu. This in-
dicated lower replication rates of the virus in STS mice,
but no difference in replication rates in BALB/c and
CcS-11 mice. To avoid virus-host interactions before
virus neuroinvasion, mice were inoculated i.c., and the
dynamics of virus growth in the brain was investigated.
Although BALB/c, CcS-11 and STS mice showed differ-
ent MST after i.c. inoculation, almost the same virus ti-
ters were observed in all investigated mouse strains at all
intervals p.i. (Figure 2). Virus replication rate is not,
therefore, the main factor influencing MST of the host.
Similarly, no differences in tissue tropism, viral load or
kinetics were observed during acute West Nile virus
infection in mouse strains C57BL/6 and C3H/HeN with
higher and lower survival rates, respectively [33].
Higher mRNA levels of cell surface marker of B-cells were
seen in brains of the mice less susceptible to TBEV infection
Mice differing in susceptibility to TBEV infection
exhibited some differences in immune cells accumula-
tion in brains during the development of encephalitis as
demonstrated by quantification of mRNA of cell-specific
markers by real-time RT-PCR. In our previous work
using BALB/c, SCID on the BALB/c background,
C57BL/6 and C57BL/6Cd8−/− mice we reported that CD8
+ T-cells have a dual role and mediate recovery, but also
immunopathology during TBE [2]. In this study, no dif-
ferences in the level of CD8 mRNA were seen between
the BALB/c, CcS-11 and STS mice after s.c. inoculation.
After i.c. inoculation, only STS mice exhibited slightly
higher levels of CD8 mRNA (but also CD4 mRNA)
than BALB/c mice at day 6 p.i., but no other differences
were observed (Figure 3B). The most interesting results
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provided quantification of mRNA for CD19, a cell sur-
face marker of B-cells. No increase of CD19 mRNA was
observed after i.c. inoculation in all mouse strains. After
s.c. inoculation, strains BALB/c and CcS-11 did not in-
crease the levels of CD19 mRNA in their brains, whereas
STS mice exhibited a significant increase (Figure 3A).
This might indicate stronger B cell infiltration in brains
of the less susceptible mice. B cells were also observed
in brains in some studies focused on flavivirus encephal-
itis [34], predominantly found in the perivascular space.
The proportion of B and T cells in the brain may vary
depending on the infecting flavivirus [35,36]. It is known
that TBEV, unlike to Japanese encephalitis and West Nile
virus infections, induces CXCL13, a B-cell chemoattract-
ant, in the CNS [37]. Although the antibody reaction is
clearly important systemically [38], the importance of
B cells infiltrating brain parenchyma in confining of the
infection is not clear.
More severe form of TBE associated with higher expression
of proinflammatory cytokines/chemokines in the brain
Accumulation of cytokines and chemokines in the CNS
may accentuate progression of encephalitis instead of
restricting viral replication [37,39-41]. Deregulated or
excess release of proinflammatory mediators by the
brain may induce tissue damage with different pathology
and disease outcome [42]. In this study, we examined
the cytokine/chemokine response in brains of the mice
differing in susceptibility to TBEV infection (Figures 4
and 5). We showed that a wide range of cytokine and
chemokine mRNAs for TNF-α, IFNγ, IL-1α, IL-1β, IL-2,
IL-6, IL-10, CCL2/MCP-1, CCL5/RANTES, IP-10, MIP-
1α, MIP-1β and others was produced in response to
TBEV infection. There was no clear correlation between
the peak of cytokine/chemokine production and the in-
crease of TBEV in the brain. After i.c. inoculation, all
mice had comparable virus titers in the CNS (Figure 2C),
but the levels of cytokine/chemokine expression differed
markedly (Figure 5). STS mice had the highest levels of
IL-1β mRNA after i.c. TBEV inoculation when com-
pared to other strains of mice. In contrast, it is known
that higher levels of IL-1β are associated with more se-
vere cases of chikungunya [43]. Most of other cytokine/
chemokine mRNAs tested were on the lowest level in
STS mice in comparison to CcS-11 and/or BALB/c
mice. The highest levels of proinflammatory cytokines/
chemokines (IFNγ, CCL3/MIP-1α, CCL2/MCP-1, IP-10)
(after s.c. and i.c. inoculation) and IL-5 (after s.c. inocu-
lation) were detected in CcS-11 mice, indicating that
these cytokines/chemokines can be associated with a
more severe form of TBE in our experimental model.
On the other hand, the lowest levels of IL-6 and CCL5/
RANTES, and also CCL3/MIP-1α and CCL4/MIP-1β
mRNAs, were demonstrated in STS mice. These data
support the theory that excessive production of pro-
inflammatory mediators could contribute to develop-
ment of more severe or acute form of TBE. Similarly to
our study, higher levels of CCL5/RANTES, CCL3/MIP-
1α, CCL4/MIP-1β and IP-10 mRNA were found to be
associated with a lethal form of West Nile virus infection
in comparison with the non-lethal form [41]. CCL2/
MCP-1 and IP-10 mRNA levels correlated well with the
susceptibility of the mouse strains to TBEV infection,
i.e., CcS-11 mice had the highest levels, BALB/c medium
and STS the lowest. These data were confirmed in two
independent experiments. Both these chemokines can
have an important role in immunopathology during
TBE. It has been demonstrated that neutralization of
CCL2/MCP-1 leads to increased survival rates in West
Nile virus-infected mice [44]. Expression of IP-10 mRNA
exhibited the biggest differences between the studied
mouse strains. The chemokine IP-10, which is IFN-γ in-
ducible and has the ability to attract activated T cells in
the CNS, has also been shown to be a potent neurotoxin
[45]. In human TBE patients, IP-10 can be detected in
serum as well as in cerebrospinal fluid [46,47]. Using
genetically deficient mice and antibody neutralization
approaches, it was demonstrated that IP-10 is critical for
the recruitment of T-cells into the CNS and survival
from West Nile virus infection in mice [48]. However,
excessively high levels of IP-10 in the CNS can be very
harmful to the host. IP-10 levels in the CNS of HIV-1
-infected individuals correlate positively with disease
progression. There is also evidence that IP-10 partici-
pates in the neuropathogenesis of SHIV-infected ma-
caques [49,50] by contributing to the degeneration of
neurons possibly through the activation of a calcium-
dependent apoptotic pathway [45,51]. Our data strongly
suggest that higher levels of IP-10 in the CNS might be
associated with more severe forms of TBE. Further stud-
ies using mice specifically knocked out for one of the
genes identified will determine their contribution to host
susceptibility to TBE. Whether the profile of the chemo-
kine production in human cases of TBE will predict the
disease outcome requires further study.
Key role of neutralizing antibodies in preventing
neuroinvasion and host fatality during TBE
The importance of neutralizing antibodies in the preven-
tion of flaviviral diseases is well accepted. As a rule, the
antibodies with relatively high affinity and avidity to the
surface proteins of TBEV virions can be detected in
neutralization test. Only such antibodies interfere with the
interaction of the virus with receptors, preventing it to
enter the cell. TBEV infection is associated with break-
down of the host blood–brain barrier [26]; therefore, the
antibodies can penetrate into the CNS. In our study, STS
mice had a strong neutralizing antibody response, CcS-11
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mice failed to produce neutralizing antibodies, and BALB/
c mice developed neutralizing antibodies but later and at
low titers (Figure 6). Therefore, our data on TBE support
the importance of neutralizing antibodies in preventing
neuroinvasion and host fatality. Similar data were obtained
in experiments with the mouse strains C3H/HeN and
DBA/2 with higher and lower susceptibility to the
Japanese encephalitis virus, respectively [40]. In hu-
man TBE patients, those who fail to produce TBEV
neutralizing antibodies usually have a very severe
course of the infection [52]. The same is seen in pa-
tients who receive vaccination against TBEV and de-
velop antibody response, but their antibodies do not
have neutralizing capacity [52].
Conclusions
In summary, our experimental model showed that earlier
and greater amounts of neutralizing antibodies could
limit neuroinvasion of TBEV and disease progression in
less susceptible mice. Moreover, we described that resist-
ant mice exhibit stronger B-cell infiltration (as measured
by quantification of changes in mRNA levels of cell sur-
face markers) but lower cytokine/chemokine production
in the CNS when compared to the more susceptible
mouse strains. The most susceptible mice have the
highest overall cytokine/chemokine production in the
CNS, particularly of CCL2/MCP-1 and IP-10, which can
elevate the primarily proinflammatory environment in
the brain, which could result in brain tissue damage and
death of the host through immunopathology. This sug-
gests an important role of cytokines and chemokines in
the immunopathogenesis of TBE. The host immune re-
sponse based on the genetic background of the host may
therefore play a central role in determining the outcome
of TBEV infection.
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TBEV and observed for lethality.
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